|
Telatinib
|
DB15393 |
[Telatinib is under investigation in clinical trial NCT03817411 (Telatinib in Combination With Capecitabine/ Oxaliplatin in 1st Line Gastric or GEJ Cancer).] |
|
Hycanthone
|
DB14061 |
[Potentially toxic, but effective antischistosomal agent, it is a metabolite of LUCANTHONE. Hycanthone was approved by the FDA in 1975 but is no longer used.] |
|
Concanamycin A
|
DB14062 |
[Concanamycin A is an H+-ATPase (vacuolar) inhibitor.] |
|
Cesium
|
DB15392 |
[Cesium is under investigation in clinical trial NCT02794675 (Intraoperative Placement of Cesium-131 Permanent Interstitial Brachytherapy in Head and Neck Cancer).] |
|
CP-526423
|
DB02089 |
|
|
Norleucine Phosphonate
|
DB02088 |
|
|
1,2-icosapentoyl-sn-glycero-3-phosphoserine
|
DB14096 |
|
|
13-cis-12-(3'-Carboxyphenyl)retinoic acid
|
DB14097 |
|
|
Cobalamin
|
DB14098 |
|
|
1,2-Distearoyllecithin
|
DB14099 |
|
|
8-epi-Cyanocobalamin
|
DB14092 |
|
|
(1,2,6,7-3H)Testosterone
|
DB14093 |
|
|
Tocopherylquinone
|
DB14094 |
|
|
Dimethyl sulfone
|
DB14090 |
|
|
Carbomer homopolymer type C
|
DB14091 |
[Carbomer homopolymer type C is a high molecular polyanionic substance tested for antiulcerogenic activity.] |
|
TA-CIN
|
DB05809 |
[TA-CIN is a subunit vaccine comprising L2/E6/E7 proteins from Human Papillomavirus (HPV16), designed to generate a strong cellular immune response against HPV-infected cells.] |
|
PI-88
|
DB05808 |
[PI-88 is a mixture of highly sulfated, monophosphorylated mannose oligosaccharides, derived from the extracellular phosphomannan of the yeast Pichia (Hansenula) holstii, with potential antiangiogenic activity.] |
|
HGTV-43
|
DB05807 |
[HGTV43 is an anti-sense treatment designed to produce T cells that are genetically resistant to HIV infection. HGTV43 is one of a number of so-called 'gene transfer vectors' developed by the biotechnology company Enzo Biochem, Inc.] |
|
Cositecan
|
DB05806 |
[Cositecan is the novel camptothecin derivative which is also known as Karenitecin. It has been developed for superior oral bioavailability and increased lactone stability. It is used to treat cancer.] |
|
NS-2359
|
DB05805 |
[NS2359 is a triple monoamine re-uptake inhibitor with a new, unique drug profile expected to yield important benefits compared to existing treatments of depression. Enhancing the function of the three neurotransmitters serotonin, noradrenalin and dopamine, NS2359 has a desired "triple-mode-of-action". This mode of action is expected to produce an optimal reduction in all disease symptoms and the possibility of an earlier onset of action compared to antidepressants already on the market.] |
